Literature DB >> 18497984

Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.

Naoko Izutsu1, Chihaya Maesawa, Masahiko Shibazaki, Hiroki Oikawa, Tadahiro Shoji, Toru Sugiyama, Tomoyuki Masuda.   

Abstract

Aberrant expression of class III beta-tubulin, TUBB3, has been reported to be one of the important mechanisms responsible for taxane resistance in diverse human malignancies. We investigated aberrant TUBB3 expression and its epigenetic modification in 66 primary tumors and 3 cell lines (OVCAR-3, JHOC-5 and JHOC-8) of ovarian cancers. Overexpression of TUBB3 protein was observed in 56 (85%) of the 66 ovarian cancers, and was significantly associated with aggressive tumor behavior (advanced stage, presence of ascites, suboptimal cytoreduction at surgery and presence of lymph node metastasis) (P<0.05). Responses to treatment with a demethylating agent (5-aza-2'-deoxycytidine, 5-Aza-CdR) and a histone deacetylase inhibitor (4-phenylbutyric acid, PBA) differed among the ovarian cancer cell lines. In 2 cell lines with weak expression of TUBB3 protein (OVCAR-3 and JHOC-8), TUBB3 induction was independently induced by treatment with 5-Aza-CdR (JHOC-8) or PBA (OVCAR-3), while neither agent markedly altered TUBB3 mRNA/protein expression in a strongly TUBB3-expressing cell line (JHOC-5). A CpG island within intron 1 was hypermethylated in 1 cell line (JHOC-8) that expressed TUBB3 weakly and required 5-Aza-CdR treatment for gene expression. A CpG island of another cell line showing faint expression of TUBB3 protein (OVCAR-3), in which a significant gain of TUBB3 expression was induced by treatment with PBA but not with 5-Aza-CdR, was hypomethylated, similarly to a cell line (JHOC-5) showing constitutive expression of TUBB3. We evaluated methylation status in this region in 14 primary tumors using methylation-specific PCR, but there was no significant relationship with TUBB3 immunoreactivity. These findings suggest that aberrant expression of TUBB3 protein might be associated with aggressive behavior of ovarian cancers, and that epigenetic modulation (DNA methylation and chromatin acetylation) might be partly involved in TUBB3 expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18497984     DOI: 10.3892/ijo_32_6_1227

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  25 in total

1.  DNA methylation is involved in the aberrant expression of miR-133b in colorectal cancer cells.

Authors:  L V Lv; Jianyu Zhou; Changwei Lin; Gui Hu; L U Yi; Juan DU; Kai Gao; Xiaorong Li
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

2.  Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

Authors:  Bingbing Yan; Fuqiang Yin; Q I Wang; Wei Zhang; L I Li
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

3.  Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.

Authors:  Song Gao; Xiaoyun Zhao; Bei Lin; Zhenhua Hu; Limei Yan; Jian Gao
Journal:  Tumour Biol       Date:  2012-06-10

Review 4.  Epigenomics and ovarian carcinoma.

Authors:  Leonel Maldonado; Mohammad Obaidul Hoque
Journal:  Biomark Med       Date:  2010-08       Impact factor: 2.851

5.  Effects of in vitro exposure of Echinococcus multilocularis metacestodes to cytostatic drugs on in vivo growth and proliferation of the parasite.

Authors:  Cora Hübner; Stefan Wiehr; Lars Kocherscheidt; Hans Wehrl; Bernd J Pichler; Andreas Schmid; Peter Kern; Peter T Soboslay
Journal:  Parasitol Res       Date:  2010-05-12       Impact factor: 2.289

6.  Mechanism and pathobiologic implications of CHFR promoter methylation in gastric carcinoma.

Authors:  Yu-Jia Gao; Yan Xin; Jian-Jun Zhang; Jin Zhou
Journal:  World J Gastroenterol       Date:  2008-08-28       Impact factor: 5.742

Review 7.  Minireview: epigenetic changes in ovarian cancer.

Authors:  Curt Balch; Fang Fang; Daniela E Matei; Tim H-M Huang; Kenneth P Nephew
Journal:  Endocrinology       Date:  2009-07-02       Impact factor: 4.736

Review 8.  Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.

Authors:  Daniela E Matei; Kenneth P Nephew
Journal:  Gynecol Oncol       Date:  2009-10-24       Impact factor: 5.482

9.  beta(III)-tubulin at the invasive margin of colorectal cancer: possible link to invasion.

Authors:  A Portyanko; P Kovalev; J Gorgun; E Cherstvoy
Journal:  Virchows Arch       Date:  2009-04-10       Impact factor: 4.064

10.  Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers.

Authors:  Dawn R Cochrane; Erin N Howe; Nicole S Spoelstra; Jennifer K Richer
Journal:  J Oncol       Date:  2009-12-15       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.